Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells

Kai-Lee Wang1,8, Shih-Min Hsia2, Jiun-Yih Yeh4, Shao-Chi Cheng1, Paulus S. Wang1,3,6,7*, Shyi-Wu Wang5*

1 Department of Physiology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China, 2 School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan, Republic of China, 3 Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China, 4 Division of Quality Assurance, Mithra Biotechnology Inc., Taipei, Taiwan, Republic of China, 5 Department of Physiology and Pharmacology, College of Medicine, Chang-Gung University, Taoyuan, Taiwan, Republic of China, 6 Ph. D. Program of Aging, College of Medicine, China Medical University, Taichung, Taiwan, Republic of China, 7 Department of Biotechnology, Asia University, Taichung, Taiwan, Republic of China, 8 The Center of General Education, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan, Republic of China

Abstract

Endocrine sensitivity, assessed by the expression of estrogen receptor (ER), has long been the predict factor to guide therapeutic decisions. Tamoxifen has been the most successful hormonal treatment in endocrine-sensitive breast cancer. However, in estrogen-insensitive cancer tamoxifen showed less effectiveness than in estrogen-sensitive cancer. It is interesting to develop new drugs against both hormone-sensitive and insensitive tumor. In this present study we examined anticancer effects of evodiamine extracted from the Chinese herb, Evodiae fructus, in estrogen-dependent and – independent human breast cancer cells, MCF-7 and MDA-MB-231 cells, respectively. Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of $1 \times 10^{-6}$ and $1 \times 10^{-5}$ M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression). The expression of ER α and β in protein and mRNA levels was down-regulated by evodiamine according to data from immunoblotting and RT-PCR analysis. Overall, our results indicate that evodiamine mediates degradation of ER and induces caspase-dependent pathway leading to inhibit proliferation of breast cancer cell lines. It suggests that evodiamine may in part mediate through ER-inhibitory pathway to inhibit breast cancer cell proliferation.

Introduction

The discovery and subsequent development of novel chemical entities into anti-cancer drugs are one of the major goals of oncologists. Compounds from traditional Chinese medicine have been examined for their anti-cancer potential in recent decades, and for those compounds that do exhibit such potential, the delineation of their mechanism of action may have an enormous influence on the development of new strategies in cancer therapies. Evodiamine is one of the important components of Chinese herb Wu-Chu-Yu. Numerous reports have revealed the effects of evodiamine including anti-angiogenesis [1], anti-tumor growth [2,3], anti-invasive and metastatic activities [4,5,6], up-regulating apoptosis [6] anti-allergic effects [7], and anti-inflammatory effects [8]. Some of these results demonstrate that evodiamine exhibits inhibitory effects on the growth and metastasis of cancer cells both in vitro and in vivo.

Breast cancers can be categorized into estrogen sensitive and estrogen insensitive patterns according to the expression of estrogen receptor (ER). Many drugs have been developed like ER antagonists (tamoxifen and clomiphene) [9], or aromatase inhibitors [10] to diminish the proliferative effects of estrogen. However, the mechanisms of how evodiamine affect the hormone-dependent cancer cells like breast cancer are poorly defined. In this study, we investigated the effects of evodiamine on the proliferation of both estrogen-dependent and independent breast cancer cell lines MDA-MB-231 and MCF-7. The intracellular signaling pathway of apoptosis and the expression of ERs were also investigated.

Materials and Methods

2.1 Compound

Evodiamine (EVO) was provided by Dr. L.C. Lin, National Research Institute of Chinese Medicine, Taipei, Taiwan, ROC. The chemical structure of EVO has been shown [2]. EVO was dissolved in dimethylsulfoxide (DMSO). The stock was stored at $-20^\circ C$ and then diluted in medium before each experiment. The final DMSO concentration did not exceed 0.1% throughout the study.

2.2 Culture with or without Evodiamine of Breast Cancer Cell Lines

The human breast cancer cell lines, including MCF-7 and MDA-MB-231 were purchased from Bioresource Collection and Research Center, Taiwan, R. O. C. MCF-7 is estrogen receptor-
alpha-positive human breast cancer cell line and MDA-MB-231 is highly-metastatic and estrogen receptor-negative human breast cancer cell line, MCF-7 and MDA-MB-231 were cultured in minimum essential medium (MEM, Gibco Laboratories, Buffalo, Grand Island, NY, USA) supplemented with 10% of fetal bovine serum (FBS, Biological Industries, KBI, Israel), 50 U/ml of penicillin G (Sigma, St. Louis, MO, USA), and 50 μg/ml of streptomycin (Sigma). The MEM for MCF-7 cell line was supplemented with 0.01 mg/ml of bovine insulin (Sigma) as previously described [11]. Cells were cultured at 37°C under aeration with 95% air +5% CO₂ and incubated with or without evodiamine (1×10⁻⁷ – 1×10⁻³ M).

2.3 Cell Proliferation-MTT Assay

The colorimetric [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] (MTT) assay was modified and performed to quantify the cell proliferation. Briefly, in the continuous treatment procedure, cells were incubated in 96-well microplates (Falcon, Franklin Lakes, NJ, USA) with MEM supplemented with 10% FBS. After 48 hr, the media was removed and replaced by either medium containing different concentration of drug or a drug-free medium (control condition). After 24, 48, 72 and 96 hrs, the media were removed and replaced by 50 μl of 1 mg/ml MTT (Sigma) in RPMI 1640 medium. After incubation for 6 hr, the MTT solution was removed and replaced by 100 μl of DMSO, and the plates were shaken for 3 min. The optical density of each condition was determined using a microplate reader (Dynatech Laboratories, Chantilly, VA, USA) at a wavelength of 570 nm after centrifugation at 14,000 rpm for 15 min. The protein concentration in the cell lysate was determined by Bradford assay [14]. Equal amounts of protein were size-fractionated by SDS-PAGE and electro-transferred to nitrocellulose membranes (Schleicher & Schuell, Inc., Keene, NH, USA). The membranes were blocked with 5% nonfat milk in TBST solution [20 mM Tris-HCl (pH 7.6), 135 mM NaCl and 0.1% Tween 20]. Cleaved PARP in MCF-7 Cells

For all groups data are presented as the mean plus or minus standard error of the mean (SEM). Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by Duncan’s multiple range test of the difference in group means compared with control mean, using the SPSS [16]. The difference between two means was considered statistically significant when p<0.05.

2.5 Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Total cellular RNA of fresh isolated cells was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using M-MuLV reverse transcriptase (New England Biolabs, Ipswich, MA, USA). Specific gene product was amplified by PCR reaction with Taq DNA polymerase (Invitrogen). Primer sets for PCR were listed as following:

ERα sense strand: 5’-GTTCCTTACCAGGCTCCACCTC-3’;
ERα antisense strand: 5’-TACCAAGAGAAGCCGGACT-3’;

Nbk/Bik sense strand: 5’-GGCAGAGGAGAATGTCCTGA-3’;
Nbk/Bik antisense strand: 5’-AGTGGTGGTGAAGCGGTC-3’;

GAPDH sense strand: 5’-CCACCCATGTGGAAATTC-3’;
GAPDH antisense strand: 5’-TCTAGACGGGACGTC-3’;

3.3 Effects of Evodiamine on the Expression of PARP and Cleaved PARP in MCF-7 Cells

PARN is a 116 KDa protein involved in the DNA repair, differentiation and chromatin structure formation. PARN is cleaved by caspase 3 during apoptosis, and possibly other caspases, into an 89 KDa fragment [17]. After being treated with evodiamine for 24 or 48 hrs at the concentration of 1×10⁻⁶ or 1×10⁻³ M, the nuclear proteins of MCF-7 cells were extracted,
and then the PARP and cleaved PARP were analyzed by Western blot. Beta-actin was adopted as an internal control protein. Figure 4 indicated that the expression of cleaved PARP increased significantly after being treated with evodiamine at the dosages and time periods described above ($p < 0.01$).

3.4 Effect of Evodiamine and Anti-estrogen Agent (ICI-182,780) on the Proliferation of MCF-7 Cells

To compare the effects of evodiamine with ICI-182,780, MCF-7 cells were treated with evodiamine ($1 \times 10^{-6}$, $1 \times 10^{-5}$ M), ICI-182,780 ($1 \times 10^{-5}$ M), or the combination of the two agents for 1 to 4 days. The cell proliferation was detected by MTT assay. As indicated in Figure 5, from day 2 to day 4, proliferations of MCF-7 cells were significantly inhibited by ICI-182,780, evodiamine, or the combination of the two agents. Only at 4-day treatment, the group of evodiamine only and evodiamine combined with ICI-182,780 displayed a significantly lower proliferation index compared with group of ICI-182,780. The group of ICI-182,780 combined with evodiamine displayed a synergistic effect.

3.5 Effects of Evodiamine on the Expression of ER$\alpha$ and ER$\beta$ in MCF-7 Cells

After being treated with evodiamine at $1 \times 10^{-6}$ or $1 \times 10^{-5}$ M for 24 or 48 hrs, the intracellular proteins were extracted for
estrogen receptor detection. The expressions of ERα were significantly inhibited by evodiamine at $1 \times 10^{-6}$ and $1 \times 10^{-5}$ M for 24- and 48-hr treatments. After evodiamine treatment, evodiamine significantly inhibited ERα expression ($p<0.01$). Evodiamine at $1 \times 10^{-5}$ M inhibited the expression of ERα markedly ($p<0.01$) (Figure 6, a and b).

According to the result of protein expression described above, ERα was more sensitive to evodiamine than ERβ. We focused on the mRNA expression of ERα in the subsequent study. MCF-7 cells were treated with evodiamine at $1 \times 10^{-6}$ and $1 \times 10^{-5}$ M and ICI-182,780 at $1 \times 10^{-2}$ M for 18 hrs. Cells were then harvested for the detection of mRNA of ERα. Results revealed that ICI-182,780 at $1 \times 10^{-2}$ M, evodiamine at $1 \times 10^{-6}$ M and $1 \times 10^{-5}$ M attenuated the expression of ERα mRNA (Figure 6c). These mRNA changes were correspondent with the results of protein expression after being treated with evodiamine.

### 3.6 Effect of Evodiamine on the Protein Expression of Bax and Nbk in MCF-7 Cells

Furthermore, the expression of pro-apoptotic bcl-2 family member, Bax and Nbk, were also examined (Figure 7 and 8). MCF-7 cells treated with evodiamine for 12 and 18 hrs could significantly up-regulate the expression of Nbk and Bax.

### Discussion

In this study we found the evodiamine significantly inhibited the proliferation of both estrogen-dependent and estrogen-independent cell lines MCF-7 and MDA-MB-231, respectively. However, the MCF-7 cells were more sensitive to evodiamine than MDA-MB-231 cells in lower doses and shorter reaction time period. According to these results, we suggested that the mechanisms of proliferation-inhibitory effects of evodiamine on these two kinds of cell lines are different. Meanwhile, in our previous study, the lactate dehydrogenase (LDH) assay indicated that MCF-7 cells treated by evodiamine at $10^{-7}$, $10^{-6}$, or $10^{-5}$ M did not cause different cytotoxicity level (data not shown). This result indicated that the decreased proliferation effect of evodiamine on MCF-7 cells was through apoptosis rather than necrosis approach. The
Figure 6. Effects of evodiamine (EVO) on the protein expression of Bax in MCF-7 cells which were treated for 18 hrs. The media for MCF-7 cells were phenol red-free DMEM/F12 supplemented with 2% charcoal/dextran-stripped FBS and estradiol ($10^{-9}$ M). Cell lysates were analyzed by Western blot. Each value presents mean plus or minus SEM. ** $p<0.01$ as compared to vehicle group.

doi:10.1371/journal.pone.0067297.g006

Apoptosis-related mechanism and the niche of estrogen receptors were then investigated. Caspases can be categorized into initiator caspases (caspase 8, 9, 10) and effector caspases (caspase 3, 7). The major effect of caspase is protein hydrolysis and it leads to the
change of cell morphology and DNA fragmentation [18]. Caspase can also digest PARP into cleaved-PARP and lead to DNA fragmentation.

According to previous studies, MCF-7 cell did not express caspase 3 [19,20], we chose caspase 7 and PARP as the indicators of apoptosis. PARP is a protein involved in a number of cellular processes involving mainly DNA repair and programmed cell death. Full-length PARP is an 116 kDa protein involved in the repair of DNA, in differentiation and in chromatin structure formation. During apoptosis, PARP is cleaved by caspase-3, and possibly other caspases, into an 89 kDa fragment [17]. It has been shown that evodiamine treatment increases the expression of cleaved caspase 7 and PARP in the present study, and the results reveal that inhibitory effects of evodiamine on proliferation of MCF-7 cells are through apoptosis rather than necrosis indeed (Figures 1, 2, 3, 4).

To investigate the anti-estrogen effects of evodiamine, we performed a test according to the theory proposed by Nolan [21], that is, if two compounds affect some cells through same mechanism, the effects induced by individual treatment of one of the drugs will not differ from the treatment of combination of the two compounds. Hence, an pure anti-estrogen compound ICI-180,782 was selected. A derivative of estradiol with a long, hydrophobic side chain at the 7 alpha position, ICI-182,780 demonstrates a pure antiestrogenic profile on all genes and in all tissues studied to date [22]. The mechanism of action of this steroidal antiestrogen differs significantly from other SERMs with mixed agonist/antagonist properties. In contrast to other SERMs, ICI-182,780 blocks ER transactivation coming from both AF-1 and AF-2 domains [23]. The drug may also impair ER dimerization, but most importantly, ICI-182,780 induces ER degradation, with a marked reduction in the cellular concentration of ER [24,25,26]. In the present study, ICI-182,780 (10$^{-5}$ M), evodiamine (10$^{-5}$ M) and ICI-182,780 (10$^{-5}$ M) plus evodiamine (10$^{-5}$ M) were treated to MCF-7 cells for 24 to 96 hrs. As indicated in Figure 5, no significant difference was observed at 24, 48, and 72 hrs following treatments. These results imply that the inhibitory effects of evodiamine on cell proliferation are similar to ICI-182,780 which is demonstrated through antiestrogenic and ER degradation pathway.

In our current study, we had also found that ER protein expression as well as mRNA levels were decrease after evodiamine treatment (Figure 6). This phenomenon is similar to ICI-182,780 treatment [24,25,26]. Moreover, previous study has found that the expression of ER$\alpha$ plays an important role in IGF-1 signaling pathway [27], down-regulation of ER$\alpha$ by chemicals or specific
Evodiamine and Breast Cancer Cells

Figure 8. Effects of evodiamine (EVO) on the protein expression of ERα (a.), ERβ (b.) and mRNA of ERα (c.) in MCF-7 cells which were treated with evodiamine for 24 or 48 hr for the detection of protein, and 18-hrs culture was for mRNA measurement. Cell lysates were analyzed by Western blot (a. and b.) or RT-PCR (c.). Each value presents mean plus or minus SEM. **p<0.01 as compared to corresponding vehicle group.
doi:10.1371/journal.pone.0067297.g008

siRNA reduces cell proliferation index [20,29]. Therefore, we suggest that evodiamine could inhibit breast cancer cell proliferation through ER-inhibitory pathway. However, the mechanisms of ER degradation and cell apoptosis are still unclear and the accurate mechanism of evodiamine has needed further investigated.

The Bcl-2-associated X protein, or BAX gene was the first identified pro-apoptotic member of the Bcl-2 protein family [30]. Bax is a pro-apoptotic Bcl-2 protein containing BH1, BH2 and BH3 domains. In healthy mammalian cells, the majority of Bax is found in the cytosol, but upon initiation of apoptotic signaling, Bax undergoes a conformation shift, and inserts into organelle membranes, primarily the outer mitochondrial membrane [31]. Bax is believed to interact with, and induce the opening of the mitochondrial voltage-dependent anion channel (VDAC). Alternatively, growing evidence suggests that activated Bax and/or Bak form an oligomeric pore, MAC in the outer membrane. This results in the release of cytochrome c and other pro-apoptotic factors from the mitochondria, often referred to as mitochondrial outer membrane permeabilization, leading to activation of caspases. This defines a direct role for Bax in mitochondrial outer membrane permeabilization, a role common to the Bcl-2 proteins containing the BH1, BH2 and BH3 domains. BCL2-interacting killer (apoptosis-inducing), also known as BIK, is a protein known to interact with cellular and viral survival-promoting proteins, such as BCL2 and the Epstein-Barr virus in order to enhance programmed cell death. Because its activity is suppressed in the presence of survival-promoting proteins, this protein is suggested as a likely target for antiapoptotic proteins. This protein shares a critical BH3 domain with other death-promoting proteins, Bax and Bak [32]. Bik is induced in MCF-7/BUS cells in the absence of estrogen signaling and plays a critical role in the antiestrogen-provoked breast cancer cell apoptosis [33]. In this study, the MCF-7 cells treated with evodiamine at earlier time point (compared to the proliferation assay condition in Figure 1) showed a significant up-regulation in the expression of Nbk and Bax (Figure 7 and 8) and led to the activation of caspase and apoptosis. On the other hand, the expressions of ERα and ERβ were also down-regulated after treatment of evodiamine in MCF-7 cells. (Figure 6) This effect also decreased the proliferation of estrogen-dependent MCF-7 cells.

In conclusion, the effects of evodiamine include the decrease of cell proliferation and up-regulation of apoptosis-related molecules, such as caspase 7, PARP, Nbk, and Bax in MCF-7 cells. These results suggest that evodiamine may in part mediate through ER-inhibitory pathway to reduce breast cancer cell proliferation.

Author Contributions
Conceived and designed the experiments: SMH SCC. Performed the experiments: SMH SCC. Analyzed the data: KLW JYY SCC. Contributed reagents/materials/analysis tools: SWW PSW. Wrote the paper: KLW JYY.

References
1. Shyu KG, Lin S, Lee CC, Chen E, Liu LC, et al. (2006) Evodiamine inhibits in vitro angiogenesis: Implication for antiangiogenicity. Life Sci 78: 2234–2245.
2. Kan SF, Huang WJ, Lin LC, Wang PS (2004) Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 110: 641–651.
3. Liao CH, Pan SL, Goh JH, Chang YL, Pai HC, et al. (2005) Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer cell line NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 26: 968–975.
4. Ogawa M, Matsubara T, Suzuki H (2001) Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol Pharm Bull 24: 917–920.
5. Ogawa M, Matsunawa T, Takahashi S, Saiki I, Suzuki H (2002) Anti-invasive and metastatic activities of evodiamine. Biol Pharm Bull 25: 1491–1493.
6. Takada Y, Kobayashi Y, Aggarwal BB (2005) Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting metastasis. J Biol Chem 280: 17203–17212.
7. Shin YW, Bae EA, Cai XF, Lee JJ, Kim DH (2007) In vitro and in vivo antiallergic effect of the fructus of Evodia rutacarpa and its constituents. Biol Pharm Bull 30: 197–199.
8. Ko HC, Wang YH, Liu KT, Chen CM, Chen CH, et al. (2007) Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutacarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol 555: 211–217.
9. Ward HW (1973) Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13–14.
10. Ponzone R, Biglia N, Jacomuzzi ME, Mariani I, Dominguez A, et al. (2006) Antihormones in prevention and treatment of breast cancer. Ann N Y Acad Sci 1089: 143–158.
11. Wang KL, Hsia SM, Chen CJ, Chang FY, Huang CY, et al. (2013) Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert Opin Ther Targets: 337–349.
12. Wang KL, Hsia SM, Mao IF, Chen ML, Wang SW, et al. (2011) Effects of polybrominated diphenyl ethers on steroidogenesis in rat Leydig cells. Hum Reprod 26: 2209–2217.
13. Wu JJ, Wang KL, Wang SW, Hwang GS, Mao IF, et al. (2011) Differential effects of nonylphenol on testosterone secretion in rat Leydig cells. Toxicology 286: 1–7.
14. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
15. Radezcki S, Kuhne CH, von Harder C, Gillissen B, Sturm I, et al. (2002) The apoptosis-promoting Bcl-2 homologues Bak and Bax/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. Oncogene 21: 227–238.
16. Steel RGD, Torrie JH (1980) Principles and Procedures of Statistics. New York: McGraw-Hill.
17. Lazebnik YA, Kaufmann SH, Denoyes S, Forier GG, Earnshaw WC (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346–347.
18. Shi Y (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9: 459–470.
19. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, et al. (2000) Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 60: 4386–4390.
20. Essmann F, Engels IH, Totzek G, Schulze-Osthoff K, Janicke RU (2004) Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res 64: 7065–7072.
21. Nolan E, Donepudi M, VanWeelden K, Flanagan L, Welsh J (1998) Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells. Mol Cell Biochem 188: 13–20.
22. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873.
23. Wakeling AE (1995) Use of pure antiestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol 49: 1543–1549.
24. Fawell SE, White R, Hoare S, Sydenham M, Page M, et al. (1990) Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 87: 6883–6887.
25. Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 89: 4037–4041.
26. Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106 (Pt 4): 1377–1388.
27. Wang LM, Xie KP, Huo HN, Shang F, Zou W, et al. (2012) Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERalpha in human breast cancer MCF-7 cells. Asian Pac J Cancer Prev 13: 1431–1437.
28. Li YW, Zhu GY, Shen XL, Chu JH, Yu ZL, et al. (2011) Furandienone inhibits cell proliferation and survival by suppressing ERalpha signaling in human breast cancer MCF-7 cells. J Cell Biochem 112: 217–224.
29. Zhao Y, Zhang Y, Liu C, Zhang J, Smith WW, et al. (2012) A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor alpha and EGF receptor signaling pathways. Cancer Prev Res (Phila) 5: 864–873.
30. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609–619.
31. Wolter KG, Hsu YT, Smith GL, Nechushtan A, Xi XG, et al. (1997) Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139: 1291–1292.
32. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, et al. (2003) Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 22: 3580–3590.
33. Hur J, Chesnes J, Coser KR, Lee RS, Geck P, et al. (2004) The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc Natl Acad Sci U S A 101: 2351–2356.